Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
BMC Vet Res ; 14(1): 148, 2018 May 02.
Artículo en Inglés | MEDLINE | ID: mdl-29716604

RESUMEN

BACKGROUND: The aim of the study was to evaluate the impact of herbal extracts on selected immunity mechanisms in clinically healthy pigeons and pigeons inoculated with the pigeon paramyxovirus type 1 (PPMV-1). For the first 7 days post-inoculation (dpi), an aqueous solution of Aloe vera or licorice extract was administered daily at 300 or 500 mg/kg body weight (BW). The birds were euthanized at 4, 7 and 14 dpi, and spleen samples were collected during necropsy. Mononuclear cells were isolated from spleen samples and divided into two parts: one part was used to determine the percentage of IgM+ B cells in a flow cytometric analysis, and the other was used to evaluate the expression of genes encoding IFN-γ and surface receptors on CD3+, CD4+ and CD8+ T cells. RESULTS: The expression of the IFN-γ gene increased in all birds inoculated with PPMV-1 and receiving both herbal extracts. The expression of the CD3 gene was lowest at 14 dpi in healthy birds and at 7 dpi in inoculated pigeons. The expression of the CD4 gene was higher in uninoculated pigeons receiving both herbal extracts than in the control group throughout nearly the entire experiment with a peak at 7 dpi. A reverse trend was observed in pigeons inoculated with PPMV-1 and receiving both herbal extracts. In uninoculated birds, increased expression of the CD8 gene was noted in the pigeons receiving a lower dose of the Aloe vera extract and both doses of licorice extracts. No significant differences in the expression of this gene were found between inoculated pigeons receiving both herbal extracts. The percentage of IgM+ B cells did not differ between any of the evaluated groups. CONCLUSIONS: This results indicate that Aloe vera and licorice extracts have immunomodulatory properties and can be used successfully to prevent viral diseases, enhance immunity and as supplementary treatment for viral diseases in pigeons.


Asunto(s)
Aloe/química , Enfermedades de las Aves/virología , Glycyrrhiza/química , Infecciones por Paramyxoviridae/veterinaria , Paramyxoviridae/efectos de los fármacos , Extractos Vegetales/uso terapéutico , Animales , Enfermedades de las Aves/tratamiento farmacológico , Enfermedades de las Aves/inmunología , Columbidae/inmunología , Columbidae/virología , Citometría de Flujo/veterinaria , Inmunidad Celular/efectos de los fármacos , Inmunidad Humoral/efectos de los fármacos , Interferón gamma/metabolismo , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/inmunología , Bazo/citología , Bazo/efectos de los fármacos , Subgrupos de Linfocitos T/efectos de los fármacos , Subgrupos de Linfocitos T/inmunología
2.
Virus Res ; 200: 19-23, 2015 Mar 16.
Artículo en Inglés | MEDLINE | ID: mdl-25645280

RESUMEN

Human metapneumovirus (hMPV) is a major cause of respiratory tract infections in children, elderly and immunocompromised hosts, for which no vaccine or treatment are currently available. Oxidative stress and inflammatory responses represent important pathogenic mechanism(s) of hMPV infection. Here, we explored the potential protective role of dietary antioxidants in hMPV infection. Treatment of airway epithelial cells with resveratrol and quercetin during hMPV infection significantly reduced cellular oxidative damage, inflammatory mediator secretion and viral replication, without affecting viral gene transcription and protein synthesis, indicating that inhibition of viral replication occurred at the level of viral assembly and/or release. Modulation of proinflammatory mediator expression occurred through the inhibition of transcription factor nuclear factor (NF)-κB and interferon regulatory factor (IRF)-3 binding to their cognate site of endogenous gene promoters. Our results indicate the use of dietary antioxidants as an effective treatment approach for modulating hMPV induced lung oxidative damage and inflammation.


Asunto(s)
Antioxidantes/farmacología , Suplementos Dietéticos/análisis , Metapneumovirus/efectos de los fármacos , Infecciones por Paramyxoviridae/virología , Línea Celular , Citocinas/genética , Citocinas/inmunología , Humanos , Metapneumovirus/genética , Metapneumovirus/fisiología , Estrés Oxidativo/efectos de los fármacos , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/inmunología , Infecciones por Paramyxoviridae/metabolismo , Quercetina/farmacología , Resveratrol , Estilbenos/farmacología , Replicación Viral/efectos de los fármacos
3.
Poult Sci ; 88(11): 2315-23, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19834081

RESUMEN

A dose titration and reduced duration medication study were performed to evaluate the current enrofloxacin treatment schedule in growing turkeys experimentally infected with avian metapneumovirus and Ornithobacterium rhinotracheale. Experimental groups of 17 four-week-old turkeys were first infected with avian metapneumovirus and 3 d later with O. rhinotracheale. Enrofloxacin treatment in the drinking water was started 24 h after O. rhinotracheale inoculation. In the dose titration study, enrofloxacin doses of 5, 10, and 20 mg/kg of BW were administered for 5 successive days. In the reduced duration medication study, the following enrofloxacin regimens were compared: 25 mg/kg of BW per day on d 0 and 2; 15 mg/kg of BW per day on d 0, 2, and 4; and 10 mg/kg of BW for 5 successive days. In both studies, all enrofloxacin treatments were equally efficacious (i.e., equally capable of shortening the course of clinical disease), eliminating O. rhinotracheale from the respiratory tract and reducing gross lesions. Ornithobacterium rhinotracheale bacteria were not recovered from any of the birds on enrofloxacin-supplemented media, indicating that none of the used treatment regimens promoted the selection of bacterial clones with reduced susceptibility or resistance to this antimicrobial agent. In conclusion, none of the alternative enrofloxacin treatment regimens yielded better results than the current prescribed treatment (i.e., 10 mg/kg of BW for 5 successive days) of O. rhinotracheale infections in turkeys. However, the reduced duration of application would offer a less time-consuming and equally effective alternative.


Asunto(s)
Infecciones por Flavobacteriaceae/veterinaria , Fluoroquinolonas/administración & dosificación , Fluoroquinolonas/farmacología , Infecciones por Paramyxoviridae/veterinaria , Enfermedades de las Aves de Corral/tratamiento farmacológico , Pavos , Animales , Antibacterianos/administración & dosificación , Antibacterianos/farmacología , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Enrofloxacina , Infecciones por Flavobacteriaceae/tratamiento farmacológico , Metapneumovirus , Ornithobacterium , Infecciones por Paramyxoviridae/tratamiento farmacológico
4.
Vet Microbiol ; 121(1-2): 94-104, 2007 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-17187945

RESUMEN

Experimental groups of 15 susceptible 3-week-old turkeys were inoculated oculonasally with avian metapneumovirus (APV) subtype A and susceptible Escherichia coli O2:K1 and Ornithobacterium rhinotracheale (ORT) bacteria, with a 3 days interval between viral and bacterial inoculation and approximately 8h between the two bacterial inoculations. The aims of the present study were to assess the efficacy of drinking-water administration of enrofloxacin for 3 and 5 days, amoxicillin for 5 days and florfenicol for 5 days for the treatment of the resulting respiratory disease, based on clinical and bacteriological examinations. Antimicrobial treatment started 1 day after dual bacterial inoculation. After infection, the birds were examined and scored for clinical signs daily, weighed at different times, and their tracheae swabbed daily. Five birds were euthanised and examined for macroscopic lesions at necropsy at 5 days post-bacterial inoculation (dpbi) and the remainder at 15dpbi. Samples of the turbinates, trachea, lungs, sinuses, air sacs, heart, pericardium and liver were collected for bacteriological examination. Recovery from respiratory disease caused by an APV/E. coli/ORT triple infection in 3-week-old turkey poults was overall most successful after enrofloxacin treatment, irrespective of treatment duration, followed by florfenicol treatment. Compared with the untreated group, clinical signs as well as ORT and E. coli multiplication in the respiratory tract were significantly reduced by both enrofloxacin treatments and the florfenicol treatment, with the enrofloxacin treatments showing significantly better reductions than the florfenicol treatment. Five-day treatment with amoxicillin, compared with the untreated group, did not cause a significant reduction in any of the aforementioned parameters.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Escherichia coli/veterinaria , Infecciones por Paramyxoviridae/veterinaria , Enfermedades de las Aves de Corral/tratamiento farmacológico , Enfermedades de las Aves de Corral/microbiología , Enfermedades Respiratorias/veterinaria , Pavos , Amoxicilina/uso terapéutico , Animales , Área Bajo la Curva , Peso Corporal/efectos de los fármacos , Enrofloxacina , Escherichia coli/crecimiento & desarrollo , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Infecciones por Flavobacteriaceae/complicaciones , Infecciones por Flavobacteriaceae/tratamiento farmacológico , Infecciones por Flavobacteriaceae/microbiología , Infecciones por Flavobacteriaceae/veterinaria , Fluoroquinolonas/uso terapéutico , Metapneumovirus/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana/veterinaria , Ornithobacterium/crecimiento & desarrollo , Infecciones por Paramyxoviridae/complicaciones , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/virología , Enfermedades de las Aves de Corral/virología , Enfermedades Respiratorias/tratamiento farmacológico , Enfermedades Respiratorias/microbiología , Enfermedades Respiratorias/virología , Organismos Libres de Patógenos Específicos , Tianfenicol/análogos & derivados , Tianfenicol/uso terapéutico , Tráquea/microbiología , Tráquea/virología
5.
Mikrobiol Z ; 61(5): 28-32, 1999.
Artículo en Ucraniano | MEDLINE | ID: mdl-10643274

RESUMEN

Administration of the homologous natural gamma-interferon for prophylaxis of infectious diseases showed that 2-3 injections of gamma-interferon prevented infectious morbidity of more than 90% of sucking pigs and new-born calves, sharply increased their preservation to 90% and above, increased their productivity by 1/3. In conditions of industrial growing of young animals therapy by this preparation of pigs and calves with colibacteriosis and parainfluenza in comparison with control significantly decreased mortality of morbid young animals, accelerated their recovery and promoted the weight gain in pigs and calves.


Asunto(s)
Antiinfecciosos/uso terapéutico , Antivirales/uso terapéutico , Enfermedades de los Bovinos/prevención & control , Infecciones por Escherichia coli/veterinaria , Interferón gamma/uso terapéutico , Infecciones por Paramyxoviridae/veterinaria , Enfermedades de los Porcinos/prevención & control , Animales , Animales Recién Nacidos , Animales Lactantes , Bovinos , Enfermedades de los Bovinos/tratamiento farmacológico , Evaluación Preclínica de Medicamentos/veterinaria , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/prevención & control , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/prevención & control , Porcinos , Enfermedades de los Porcinos/tratamiento farmacológico
6.
Vopr Virusol ; 37(4): 207-11, 1992.
Artículo en Ruso | MEDLINE | ID: mdl-1281946

RESUMEN

Mice infected with influenza A/Aichi/2/68 (H3N2) virus or Sendai/960 paramyxovirus were treated by inhalations of aerosol aprotinin, a broad spectrum inhibitor of proteinases. A course of inhalations of finely dispersed aerosol aprotinin including 4 exposures of 35-40 min each daily for 6 days provided respiratory administration of aprotinin in a dose about 100 kallikrein-inhibiting U/mouse per day. In mice treated by aprotinin inhalations, histological examinations showed decreased pulmonary pathology, and their body weights increased as much as in uninfected animals. In the placebo group, the weight decreased until the death of the animals. The protective effect of aprotinin inhalations was 40-80% with inoculation doses 10-100 MLD50/mouse. The treated animals died 2-4 days later than those in the placebo group. The results indicate the expedience of inhalation therapy with aerosol aprotinin in influenza and paramyxovirus respiratory infections.


Asunto(s)
Aprotinina/administración & dosificación , Virus de la Influenza A , Infecciones por Orthomyxoviridae/tratamiento farmacológico , Virus de la Parainfluenza 1 Humana , Infecciones por Paramyxoviridae/tratamiento farmacológico , Administración por Inhalación , Animales , Peso Corporal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Pulmón/efectos de los fármacos , Pulmón/patología , Ratones , Infecciones por Orthomyxoviridae/patología , Infecciones por Paramyxoviridae/patología
7.
Vopr Virusol ; 36(5): 389-92, 1991.
Artículo en Ruso | MEDLINE | ID: mdl-1666476

RESUMEN

Deitiforin in HEp-2 cell culture was shown to inhibit replication of the reference PIV-3 strain when administered 1 hour before virus inoculation. The most marked effect of the drug was observed in the first 4 days of observation. In experimental newborn mice infected with parainfluenza virus 3 deitiforin protected the animals from developing the infection. In humans given deitiforin reaction to vaccination was found to develop 5-6 times more rarely than in the control group, PIV-3 could be isolated twice as rarely, and a diagnostically significant rise of specific antibody levels was observed less frequently.


Asunto(s)
Antivirales/uso terapéutico , Virus de la Parainfluenza 3 Humana , Infecciones por Paramyxoviridae/tratamiento farmacológico , Adulto , Animales , Animales Lactantes , Anticuerpos Antivirales/sangre , Línea Celular , Células Cultivadas/efectos de los fármacos , Células Cultivadas/microbiología , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Humanos , Ratones , Compuestos Orgánicos , Virus de la Parainfluenza 3 Humana/inmunología , Infecciones por Paramyxoviridae/inmunología , Factores de Tiempo , Vacunas Virales/inmunología
8.
Antiviral Res ; 14(4-5): 215-25, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-1965109

RESUMEN

The toxicity and antiviral efficacy of carbocyclic 3-deazaadenosine (Cc3Ado) against respiratory syncytial (RSV) and parainfluenza type 3 (PIV3) virus infections were tested in tissue culture and in cotton rats. The mean median efficacious dose (ED50) of Cc3Ado in HEp2 cells against RSV and PIV3 was 9 and 14 micrograms/ml, respectively. These values were 85- and 55-fold less than the median inhibitory (toxic) dose (ID50) of Cc3Ado in this cell line (750 micrograms/ml), and similar to values obtained for ribavirin. Cc3Ado exhibited no significant antiviral activity against influenza A, influenza B, adeno type 5 or adeno type 7 viruses (all ED50 were greater than 1000 micrograms/ml). In cotton rats, animals given greater than or equal to 1 mg/kg/day Cc3Ado intraperitoneally on days 1, 2 and 3 after experimental challenge with virus, consistently had significant reductions in pulmonary RSV and PIV3 titers compared to pulmonary virus titers in comparably treated control animals. The minimum efficacious dose of ribavirin given under the same conditions was 30 mg/kg/day. Cc3Ado was also efficacious in cotton rats when given orally by gavage, or when different administration schedules were used. The median efficacious dose of Cc3Ado when given orally was 10 mg/kg/day. No significant toxic effects were noted in cotton rats, even in animals given 20 mg/kg daily for eight consecutive days.


Asunto(s)
Antivirales/toxicidad , Virus de la Parainfluenza 3 Humana/efectos de los fármacos , Virus Sincitiales Respiratorios/efectos de los fármacos , Tubercidina/análogos & derivados , Replicación Viral/efectos de los fármacos , Animales , Línea Celular , Evaluación Preclínica de Medicamentos , Femenino , Humanos , Masculino , Virus de la Parainfluenza 3 Humana/crecimiento & desarrollo , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/patología , Ratas , Virus Sincitiales Respiratorios/crecimiento & desarrollo , Infecciones por Respirovirus/tratamiento farmacológico , Infecciones por Respirovirus/patología , Tubercidina/farmacología , Tubercidina/toxicidad
9.
Antiviral Res ; 14(4-5): 237-47, 1990.
Artículo en Inglés | MEDLINE | ID: mdl-1965110

RESUMEN

LY253963, the sodium salt of 1,3,4-thiadiazol-2-ylcyanamide, was evaluated in tissue culture and in cotton rats for toxicity and antiviral efficacy against respiratory syncytial (RSV) and parainfluenza type 3 (PIV3) viruses. The selective index (ratio of the median toxic dose: median efficacious dose) of LY253963 in HEp2 tissue culture cells was greater than 100 against both RSV and PIV3. When given intraperitoneally to cotton rats, the minimum protective dose of LY253963 against both of these viruses was between 1 and 3 mg/kg/day. In contrast, doses of LY253963 as high as 30 mg/kg/day, administered orally after experimental inoculation of virus, did not significantly reduce pulmonary virus titers in treated animals compared to control animals given placebo. No toxic effects were noted in cotton rats, even in those given 20 mg/kg/day for eight consecutive days.


Asunto(s)
Antivirales/farmacología , Nitrilos/farmacología , Infecciones por Paramyxoviridae/tratamiento farmacológico , Virus Sincitiales Respiratorios/efectos de los fármacos , Infecciones por Respirovirus/tratamiento farmacológico , Respirovirus/efectos de los fármacos , Tiadiazoles/farmacología , Animales , Antivirales/administración & dosificación , Línea Celular , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Humanos , Infecciones por Paramyxoviridae/patología , Ratas , Infecciones por Respirovirus/patología , Ribavirina/administración & dosificación , Ribavirina/farmacología
10.
Zhong Xi Yi Jie He Za Zhi ; 10(4): 222-4, 197-8, 1990 Apr.
Artículo en Chino | MEDLINE | ID: mdl-2169355

RESUMEN

The present study was carried out by using the plaque formation test, microdosage cytopathic effect (CPE) method, and mice nasal-cavity-attacking method to observe the antiviral and interferon-inducing effect of Fang-Gan mixture (FGM). The results showed that FGM has direct respiratory syncytia virus (RSV) inactivation effect, and protection effect after mice infected by RSV. FGM could also decrease mice death rate (P less than 0.01) in the experimentation of using parainfluenza virus to attack them, and work in coordination with interferon induced by Newcastle disease virus. After 8, 16, 24, 32 hours of injecting FGM into mice abdominal cavity, the authors used CPE method to determine interferon titer of L929 cells, and found that the highest interferon titer was 98.23 mu/m at the 24th hour. The interferon induced by FGM was in keeping with the nature of Type I interferon. The results suggested that FGM might have strong antiviral effect which is achieved by inducing interferon.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Interferón Tipo I/biosíntesis , Virus Sincitiales Respiratorios/efectos de los fármacos , Animales , Antivirales , Medicamentos Herbarios Chinos/uso terapéutico , Femenino , Inductores de Interferón , Masculino , Ratones , Ratones Endogámicos ICR , Infecciones por Paramyxoviridae/tratamiento farmacológico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA